Maria Kavallaris

Sep 6, 2024 | nature.com | Paul Joyce |María José Alonso |Michelle S. Bradbury |Maria Kavallaris |Robert LANGER |Twan Lammers | +7 more

AbstractNanomedicines have created a paradigm shift in healthcare. Yet fundamental barriers still exist that prevent or delay the clinical translation of nanomedicines. Critical hurdles inhibiting clinical success include poor understanding of nanomedicines’ physicochemical properties, limited exposure in the cell or tissue of interest, poor reproducibility of preclinical outcomes in clinical trials, and biocompatibility concerns.